Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy
Reference44 articles.
1. Pisani J, Bonduelle Y. Opportunities and barriers in the biosimilar market: evolution or revolution for generics companies? London: Pricewaterhouse Coopers LLP 2006 ( www.pwc.com/uk/strategy )
2. Avalere Health. Estimating US savings from follow-on biologics. Biosimilars: how much entry and price competition will result. OHE Conference. London, June 2, 2009
3. Horikawa H, Tsubouchi M, Kawakami K. Industry views of biosimilar development in Japan. Health Policy 2009; 91: 189–94
4. Lanthier M, Behrman R, Nardinelli C. Economic issues with follow-on protein products. Nat Rev Drug Discov 2008; 7: 733–7
5. Grabowski H, Wang R. The quantity and the quality of worldwide new drug introductions 1982–2003. Health Aff 2006; 25: 452–60
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献